MAVENIR
23.2.2024 08:01:34 CET | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces that it is in the advanced commercial phase of an Open RAN network pilot deployment for Vodafone Idea Limited (Vi). The deployment now underway, which commenced in September 2023, covers key launch sites and is currently carrying live commercial traffic ahead of a planned large-scale deployment. The pilot marks the first O-RAN-compliant deployment into Vodafone Idea’s network, utilising the N78 and N258 millimeter-wave (mmWave) spectrum bands and B1 supporting NSA architecture.
Mavenir and Red Hat continue to work with customers and partners to offer one of the strongest open RAN ecosystems available today. In this instance, Mavenir is providing a complete, end-to-end cloud-native Open RAN system for the Indian operator – incorporating a Distributed Unit (DU) solution based on commercial off-the-shelf (COTS) hardware and Mavenir’s scalable and modular OpenBeam™ Radios, Centralized Unit (CU) plus full Mavenir Remote Radio Unit (RRU) and RAN software capabilities all running on Red Hat OpenShift, the industry’s leading hybrid cloud application platform powered by Kubernetes, – optimised for deployment in urban environments.
Commenting on the deployment, Jagbir Singh, Chief Technical Officer of Vodafone Idea, said, “We are proud to be demonstrating our leadership in exploring next-generation radio solutions that can deliver sustainable advantages to our business and to our customers. This Open RAN deployment, delivered through Mavenir’s innovation and joint technological strategic initiatives, is in sync with our technology transformation roadmap and enriched vendor ecosystem. Working in partnership with solution of Mavenir, we see a major role ahead for Open RAN technology in delivering the network enhanced capabilities, better TCO and open interfaces that will push the industry forward in new ways.”
BG Kumar, President Access Networks, Platforms, and Digital Enablement at Mavenir, said: “Vodafone Idea is leading the way in bringing the clear benefits of Open RAN technology to the Indian market, which is characterized by unique challenges and opportunities, including its very large subscriber base, high level of population density and diverse deployment environments. Mavenir is actively engaged in building out the ecosystem that will deliver next-generation Open RAN technology platforms enhancing customer experience across India – powering greater growth, flexibility, customisation and customer-focused innovation, while driving down CapEx and OpEx for operators.”
Honoré LaBourdette, acting senior vice president, Global Telco, and vice president, Telco, Media and Entertainment Partner Ecosystem, Red Hat, said: “Red Hat is dedicated to helping service providers implement open RAN solutions for more freedom of choice and new 5G use cases like 5G core, edge computing, AI/ML and more. By collaborating with Mavenir, Red Hat OpenShift helps provide Vodafone Idea with a reliable platform that can scale to meet their customer’s needs.”
Red Hat, the Red Hat logo and OpenShift are trademarks or registered trademarks of Red Hat, Inc. or its subsidiaries in the U.S. and other countries.
About Vodafone Idea
Vodafone Idea Limited is an Aditya Birla Group and Vodafone Group partnership. It is amongst India’s leading telecom service provider. The company provides pan India Voice and Data services across 2G, 3G and 4G platforms. Company holds large spectrum portfolio including mid band 5G spectrum in 17 circles and mmWave 5G spectrum in 16 circles. To support the growing demand for data and voice, the company is committed to deliver delightful customer experiences and contribute towards creating a truly ‘Digital India’ by enabling millions of citizens to connect and build a better tomorrow. The company is developing infrastructure to introduce newer and smarter technologies, making both retail and enterprise customers future ready with innovative offerings, conveniently accessible through an ecosystem of digital channels as well as extensive on-ground presence. The company’s equity share are listed on National Stock Exchange (NSE) and the BSE in India. The company offers products and services to its customers in India under the TM Brand name “Vi”.
For more information, please visit: www.MyVi.in
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscriber. www.mavenir.com
Meet Mavenir at Mobile World Congress 2024 (Barcelona, Feb 26 – 29 2024)
To explore our latest innovations, MWC show announcements and learn more about how Mavenir is delivering the Future of Networks – Today, visit our team in Hall 2 (Stand 2H60).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222777201/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release
Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom